MABp1 targeting interleukin‐1α in hidradenitis suppurativa ineligible for adalimumab treatment: results of the open‐label extension period. (1st January 2021) - Kanni, T.; Argyropoulou, M.; Dinarello, C. A.; Simard, J.; Giamarellos‐Bourboulis, E. J.